Leerink Partners maintained a 'Hold' rating on Pfizer (Pfizer) in a report released yesterday. The company's stock price closed at $27.80 yesterday.
Currently, the market consensus among analysts regarding Pfizer is "moderate buy," with an average target price of $28.63, which is 2.99% higher than the current level. In another report released yesterday, UBS also maintained a "hold" rating for the stock, with a target price of $27.00.
According to Pfizer's latest financial report for the quarter ending June 28, the company reported quarterly revenue of $15.03 billion and a net loss of $246 million. In contrast, during the same period last year, the company's revenue was $14.65 billion and its net profit was $2.91 billion.
Based on the trading activities of 19 insiders recently, the market sentiment towards these shares among insiders is positive. This indicates that in the past quarter, there has been an increase in the number of insiders purchasing PFE shares compared to earlier this year. The most recent instance occurred in August 2026, when PFE's Senior Vice President and Control Officer JENNIFER B DAM sold 3,278 tokens for a total of $83,261.20.
More about PFE:
Disclaimer and Disclosure
Report an issue











